Literature DB >> 28191499

The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.

Madison Miller1, Nitin Shirole2, Ruxiao Tian1, Debjani Pal3, Raffaella Sordella2.   

Abstract

As the most mutated gene in cancer, it is no surprise that TP53 has been the center of cancer biology discourse since its discovery in the late 1970s. Although early demonstrations of p53's role in the modulation of cell proliferation and survival solidified its classification as a tumor suppressor and transcription factor, our conceptualization of p53 is ever-evolving. Here, we present novel evidence of the role of alternative splicing isoforms, truncating/separation-of-function mutations, and hotspot silent mutations in the regulation of p53's activities.

Entities:  

Keywords:  Alternative splicing; Gain-of-function; Hot-spot mutations; Loss-of-function; Separation-of-function; Silent mutations; Truncating mutations; p53; p53 isoforms; p53-psi

Year:  2016        PMID: 28191499      PMCID: PMC5298884     

Source DB:  PubMed          Journal:  J Cancer Biol Res        ISSN: 2373-9436


  54 in total

1.  Separation-of-function mutants reveal critical roles for RAG2 in both the cleavage and joining steps of V(D)J recombination.

Authors:  J X Qiu; S B Kale; H Yarnell Schultz; D B Roth
Journal:  Mol Cell       Date:  2001-01       Impact factor: 17.970

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  p53 suppresses the self-renewal of adult neural stem cells.

Authors:  Konstantinos Meletis; Valtteri Wirta; Sanna-Maria Hede; Monica Nistér; Joakim Lundeberg; Jonas Frisén
Journal:  Development       Date:  2006-01       Impact factor: 6.868

4.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

5.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.

Authors:  W E Mercer; M T Shields; M Amin; G J Sauve; E Appella; J W Romano; S J Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

7.  The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

Authors:  I Roth; H Campbell; C Rubio; C Vennin; M Wilson; A Wiles; G Williams; A Woolley; P Timpson; M V Berridge; N Fleming; M Baird; A W Braithwaite
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

8.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.

Authors:  Serif Senturk; Zhan Yao; Matthew Camiolo; Brendon Stiles; Trushar Rathod; Alice M Walsh; Alice Nemajerova; Matthew J Lazzara; Nasser K Altorki; Adrian Krainer; Ute M Moll; Scott W Lowe; Luca Cartegni; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-29       Impact factor: 11.205

View more
  10 in total

1.  Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets.

Authors:  Ellen Heitzer; Sandra Sunitsch; Magdalena M Gilg; Birgit Lohberger; Beate Rinner; Karl Kashofer; Nicole Stündl; Peter Ulz; Joanna Szkandera; Andreas Leithner; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging.

Authors:  Ajaykumar C Morani; Abdelrahman K Hanafy; Nisha S Ramani; Venkata S Katabathina; Sireesha Yedururi; Anil K Dasyam; Srinivasa R Prasad
Journal:  Radiol Imaging Cancer       Date:  2020-03-13

3.  Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy.

Authors:  Mark J de Keijzer; Daniel J de Klerk; Lianne R de Haan; Robert T van Kooten; Leonardo P Franchi; Lionel M Dias; Tony G Kleijn; Diederick J van Doorn; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

4.  Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.

Authors:  Anthony Wood; Saby George; Nabil Adra; Sreenivasulu Chintala; Nur Damayanti; Roberto Pili
Journal:  Invest New Drugs       Date:  2019-10-25       Impact factor: 3.850

Review 5.  Should mutant TP53 be targeted for cancer therapy?

Authors:  Andreas Strasser; Gemma L Kelly; Zilu Wang
Journal:  Cell Death Differ       Date:  2022-03-24       Impact factor: 12.067

6.  Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.

Authors:  Carina Neitzel; Nina Seiwert; Anja Göder; Erika Diehl; Carina Weber; Georg Nagel; Svenja Stroh; Birgit Rasenberger; Markus Christmann; Jörg Fahrer
Journal:  Cells       Date:  2019-07-30       Impact factor: 6.600

Review 7.  Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities.

Authors:  Carina Neitzel; Philipp Demuth; Simon Wittmann; Jörg Fahrer
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

8.  Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin.

Authors:  Evgeny M Kirilin; Timur I Fetisov; Natalia I Moiseeva; Ekaterina A Lesovaya; Lidia A Laletina; Leyla F Makhmudova; Angelika E Manikaylo; Liliya Y Fomina; Denis A Burov; Beniamin Yu Bokhyan; Victoria Y Zinovieva; Alice S Vilkova; Larisa V Mekheda; Nikolay A Kozlov; Alexander M Scherbakov; Gennady A Belitsky; Vytas Švedas; Kirill I Kirsanov; Marianna G Yakubovskaya
Journal:  Cancers (Basel)       Date:  2022-04-01       Impact factor: 6.639

9.  Rare and potentially pathogenic variants in hydroxycarboxylic acid receptor genes identified in breast cancer cases.

Authors:  Cierla McGuire Sams; Kasey Shepp; Jada Pugh; Madison R Bishop; Nancy D Merner
Journal:  BMC Med Genomics       Date:  2021-12-01       Impact factor: 3.063

10.  TP53-Deficient Angiosarcoma Expression Profiling in Rat Model.

Authors:  Urszula Smyczyńska; Damian Strzemecki; Anna M Czarnecka; Wojciech Fendler; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Magdalena Guzowska; Kamil Synoradzki; Łukasz Cheda; Zbigniew Rogulski; Paweł Grieb
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.